Cargando…

Pre-clinical investigation of liquid sirolimus for local drug delivery

INTRODUCTION: Sirolimus is currently being explored as an alternative drug to paclitaxel for the treatment of peripheral artery disease (PAD). To date, sirolimus has only been used as drug coatings for stents and balloons and no studies have yet demonstrated the delivery of sirolimus in liquid form....

Descripción completa

Detalles Bibliográficos
Autores principales: Todd, Meagan, Liu, Linda B., Saul, Justin M., Yazdani, Saami K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540618/
https://www.ncbi.nlm.nih.gov/pubmed/37781304
http://dx.doi.org/10.3389/fcvm.2023.1184816
_version_ 1785113748804993024
author Todd, Meagan
Liu, Linda B.
Saul, Justin M.
Yazdani, Saami K.
author_facet Todd, Meagan
Liu, Linda B.
Saul, Justin M.
Yazdani, Saami K.
author_sort Todd, Meagan
collection PubMed
description INTRODUCTION: Sirolimus is currently being explored as an alternative drug to paclitaxel for the treatment of peripheral artery disease (PAD). To date, sirolimus has only been used as drug coatings for stents and balloons and no studies have yet demonstrated the delivery of sirolimus in liquid form. The purpose of this pilot study was to investigate the feasibility of the delivery of liquid sirolimus into arterial segments in a benchtop peripheral artery bioreactor. METHODS: The feasibility to deliver liquid therapy was first tested on four drug delivery devices using a fluorescently tagged liquid drug and an ex vivo porcine artery benchtop model. The four devices included the Bullfrog micro-infusion device, ClearWay RX catheter, Occlusion perfusion catheter (OPC), and the targeted adjustable pharmaceutical administration system (TAPAS). Penetration of the fluorescently tagged drug was measured via microscopic imaging and quantification of the depth of drug penetration into all device-treated tissue. Based on the penetration outcome, we then selected a single device to deliver liquid sirolimus into the ex vivo porcine artery model undergoing physiological flow and pressure conditions. The liquid sirolimus-treated arteries were collected from the ex vivo bioreactor at 1- and 24-hour post-delivery and arterial drug retention analyzed by liquid chromatography-tandem mass spectrometry. RESULTS: Fluorescent microscopy demonstrated that drug delivery with the OPC had greater drug penetration into the medial wall as compared to other devices (OPC: 234 ± 161 µm; TAPAS: 127 ± 68 µm; ClearWay: 118 ± 77 µm; Bullfrog: 2.12 ± 3.78 µm; p = 0.098). The results of the ex vivo flow-circuit bench top model showed that the OPC device successfully delivered the liquid sirolimus at 1-hour (5.17 ± 4.48 ng/mg) and 24-hour (0.78 ± 0.55 ng/mg). CONCLUSIONS: These results demonstrate for the first time the ability to deliver liquid sirolimus directly to the medial layer of an artery via a liquid delivery catheter.
format Online
Article
Text
id pubmed-10540618
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105406182023-09-30 Pre-clinical investigation of liquid sirolimus for local drug delivery Todd, Meagan Liu, Linda B. Saul, Justin M. Yazdani, Saami K. Front Cardiovasc Med Cardiovascular Medicine INTRODUCTION: Sirolimus is currently being explored as an alternative drug to paclitaxel for the treatment of peripheral artery disease (PAD). To date, sirolimus has only been used as drug coatings for stents and balloons and no studies have yet demonstrated the delivery of sirolimus in liquid form. The purpose of this pilot study was to investigate the feasibility of the delivery of liquid sirolimus into arterial segments in a benchtop peripheral artery bioreactor. METHODS: The feasibility to deliver liquid therapy was first tested on four drug delivery devices using a fluorescently tagged liquid drug and an ex vivo porcine artery benchtop model. The four devices included the Bullfrog micro-infusion device, ClearWay RX catheter, Occlusion perfusion catheter (OPC), and the targeted adjustable pharmaceutical administration system (TAPAS). Penetration of the fluorescently tagged drug was measured via microscopic imaging and quantification of the depth of drug penetration into all device-treated tissue. Based on the penetration outcome, we then selected a single device to deliver liquid sirolimus into the ex vivo porcine artery model undergoing physiological flow and pressure conditions. The liquid sirolimus-treated arteries were collected from the ex vivo bioreactor at 1- and 24-hour post-delivery and arterial drug retention analyzed by liquid chromatography-tandem mass spectrometry. RESULTS: Fluorescent microscopy demonstrated that drug delivery with the OPC had greater drug penetration into the medial wall as compared to other devices (OPC: 234 ± 161 µm; TAPAS: 127 ± 68 µm; ClearWay: 118 ± 77 µm; Bullfrog: 2.12 ± 3.78 µm; p = 0.098). The results of the ex vivo flow-circuit bench top model showed that the OPC device successfully delivered the liquid sirolimus at 1-hour (5.17 ± 4.48 ng/mg) and 24-hour (0.78 ± 0.55 ng/mg). CONCLUSIONS: These results demonstrate for the first time the ability to deliver liquid sirolimus directly to the medial layer of an artery via a liquid delivery catheter. Frontiers Media S.A. 2023-09-15 /pmc/articles/PMC10540618/ /pubmed/37781304 http://dx.doi.org/10.3389/fcvm.2023.1184816 Text en © 2023 Todd, Liu, Saul and Yazdani. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Todd, Meagan
Liu, Linda B.
Saul, Justin M.
Yazdani, Saami K.
Pre-clinical investigation of liquid sirolimus for local drug delivery
title Pre-clinical investigation of liquid sirolimus for local drug delivery
title_full Pre-clinical investigation of liquid sirolimus for local drug delivery
title_fullStr Pre-clinical investigation of liquid sirolimus for local drug delivery
title_full_unstemmed Pre-clinical investigation of liquid sirolimus for local drug delivery
title_short Pre-clinical investigation of liquid sirolimus for local drug delivery
title_sort pre-clinical investigation of liquid sirolimus for local drug delivery
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540618/
https://www.ncbi.nlm.nih.gov/pubmed/37781304
http://dx.doi.org/10.3389/fcvm.2023.1184816
work_keys_str_mv AT toddmeagan preclinicalinvestigationofliquidsirolimusforlocaldrugdelivery
AT liulindab preclinicalinvestigationofliquidsirolimusforlocaldrugdelivery
AT sauljustinm preclinicalinvestigationofliquidsirolimusforlocaldrugdelivery
AT yazdanisaamik preclinicalinvestigationofliquidsirolimusforlocaldrugdelivery